Lucius LuciRip Ripretinib 50mg

Product Information

• Product name: LuciRip Ripretinib 50mg
• Manufacturer / brand: Laos Lucius Pharma
• Active ingredient: Ripretinib
• Current strength: 50mg
• SKU: Product ID 3128
• Site category: general medicines

Product Summary

LuciRip Ripretinib 50mg is an AISTIKA-listed product supplied by Laos Lucius Pharma. This page summarizes the product identity, strength, SKU, site category, and public medical reference information. Product name, manufacturer, packaging, and strength follow this AISTIKA product page.

Active Ingredient and Reference Data

Ripretinib is the active ingredient used for this product page. Public prescribing information for Ripretinib was used for the medical reference sections. Medical details are provided for reference and must be interpreted by a qualified healthcare professional.

Mechanism of Action

Ripretinib is a tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet derived growth factor receptor A (PDGFRA) kinase, including wild type, primary, and secondary mutations. Ripretinib also inhibits other kinases in vitro, such as PDGFRB, TIE2, VEGFR2, and BRAF.

Reference Indications

Ripretinib is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib. Ripretinib is a kinase inhibitor indicated for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with 3 or more kinase inhibitors, including imatinib.

Reference Dosage and Administration

Recommended Dosage : 150 mg orally once daily with or without food.

With this 50mg product, that corresponds to 3 x 50mg tablets when that reference dose is clinically appropriate.

This reference dosage is not an individualized prescription. Dose changes, treatment interruptions, or discontinuation must be directed by a physician.

Important Safety Information

Palmar-Plantar Erythrodysesthesia Syndrome : Based on severity, withhold Ripretinib and resume at same or reduced dose. ( 2.2 , 5.1 ) New Primary Cutaneous Malignancies : Perform dermatologic evaluations when initiating Ripretinib and routinely during treatment. Hypertension : Do not initiate Ripretinib in patients with uncontrolled hypertension and monitor blood pressure during treatment. Based on severity, withhold Ripretinib and then resume at same or reduced dose or permanently discontinue. ( 2.2 , 5.3 ) Cardiac Dysfunction : Assess ejection fraction by echocardiogram or MUGA scan prior to initiating Ripretinib and during treatment, as clinically indicated. Permanently discontinue Ripretinib for Grade 3 or 4 left ventricular systolic dysfunction.

Common Adverse Reactions and Monitoring

The most common Grade 3 or 4 laboratory abnormalities (≥4%) were increased lipase and decreased phosphate. Unless otherwise specified, the pooled safety population described in the reflect exposure to Ripretinib as a single agent in 351 patients with advanced solid tumors enrolled in either an open-label dose finding with cohort expansion trial or INVICTUS. Among the patients who received Ripretinib in these trials, 52% were exposed for 6 months or longer and 21% were exposed for greater than one year. Gastrointestinal Stromal Tumor Patients Who Received Prior Treatment with Imatinib, Sunitinib and Regorafenib The safety of Ripretinib was evaluated in INVICTUS .

Drug Interactions and Special Populations

Strong CYP3A Inducers : Avoid concomitant use of strong CYP3A inducers. Moderate CYP3A Inducers : Avoid concomitant use of moderate CYP3A inducers. If a moderate CYP inducer cannot be avoided, increase ripretinib dose frequency to twice daily. Strong and Moderate CYP3A Inducers Clinical Impact Coadministration of Ripretinib with a strong CYP3A inducer decreased the exposure of ripretinib and its active metabolite (DP-5439), which may decrease Ripretinib anti-tumor activity . Coadministration of Ripretinib with moderate CYP3A inducers is predicted to decrease the exposure of ripretinib and its active metabolite (DP-5439), which may decrease Ripretinib anti-tumor activity . Prevention or Management Avoid concomitant use of Ripretinib with strong CYP3A inducers. Avoid concomitant use of Ripretinib with moderate CYP3A inducers.

Storage and Purchase Notes

Store according to the package or pharmacist instructions and keep out of reach of children. Before ordering, confirm product name, strength, quantity, price, shipping details, and payment method. After receipt, check packaging, batch number, expiration date, and storage conditions.

Sources

Sources: QINLOCK public prescribing information; openFDA/DailyMed public label data. These sources are used for public medical reference. Product information follows this AISTIKA product page.

DisclaimerThis page is for product information and public-label reference only. It does not provide diagnosis, prescription, or individualized medical advice. Consult a physician for treatment decisions.